Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]
Upstream Bio, Inc. (UPB)
Company Research
Source: Seeking Alpha
Verekitug's efficacy and dosing profile may surpass competitors, yet pivotal asthma and COPD data won't arrive until later 2026 or after. The analyst firm community is generally bullish long-term, but another capital raise is expected before commercialization, with $100M+ revenue not projected until 2030. An analysis around Upstream Bio follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » KS Kim/iStock via Getty Images Shares of inflammatory disease biotech Upstream Bio, Inc. ( UPB ) have rallied by roughly 60% since reporting potentially best-in-class data for its asset verekitug in a Phase 2 trial in early September 2025. In addition to More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biot
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.MarketBeat
- Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.MarketBeat
- Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]Seeking Alpha
- Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.MarketBeat
UPB
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- UPB's page on the SEC website